Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Aug 24, 2016 (10 years ago)

Phenylephrine HCI Injection

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Lack of Assurance of Sterility: a recent FDA inspection at the manufacturing firm raised concerns that product sterility may be compromised.

Cause type: Sterility / contamination

A product that must be sterile could not be assured sterile, or was contaminated. A top reason for injectables, eye drops and IV products - loss of sterility assurance can lead to serious infections. All sterility / contamination recalls.

What was recalled

Phenylephrine HCI Injection, USP, 10mg/mL, packaged in a) 5 mL Vial, 50 mg/5 mL (NDC 66758-016-03), 25 x 5 mL Vials per carton (NDC 66758-016-04) and b) 10 mL Vials, 100 mg/10 mL (NDC 66758-017-01), Rx only, Manufactured for: Sandoz Inc., Princeton, NJ 08540.

Affected NDCs 66758-0016-03 66758-0016-04 66758-0017-01

Compare with the code on your package — it is the most precise check available.

Drug: Phenylephrine

Recalling firm
Sandoz Inc
NDC code
66758-016-03
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1514-2016 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Phenylephrine recalls

See all

Other recalls by Sandoz Inc

All 2016 recalls
Class III · Low risk

Focalin XR

Labeling: Incorrect or Missing Lot and/or Exp Date

Ongoing Labeling / mix-up Sandoz Inc D-0608-2026